Concepedia

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Amit Bardia, Jun Wu, Q. Zhang, Zbigniew Nowecki, F. Melo Cruz, S-B. Kim, Christian Schem, Alberto J. Montero,

Annals of Oncology · 2022 · 58 citations · 1 references

Open access

Concepts

MedicineEndocrinologyOncologyBreast OncologyEndocrine OncologyEndocrine PharmacotherapyBreast Cancer PharmacotherapyHer2-positive Breast CancerHormonal Cancer TherapyHormonal TherapyMetastatic Breast CancerBreast Cancer Endocrine TherapyBreast Cancer Hormonal TherapyBreast Cancer Hormone TherapyCombination Endocrine TherapyHer2-positive Breast Cancer TherapyHormone Receptor-positive Breast Cancer TherapyMetastatic Breast Cancer TreatmentMetastatic Her2-positive Breast Cancer

References

1

211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study

M. Martín Jiménez, Elgene Lim, Amit Bardia et al. · Annals of Oncology · 2022 · 58 citations · Full text

Medicine, Endocrinology, Oncology +16